OTC · Health care

Oncotelic Therapeutics, Inc. (OTLC)

At June 30, 2026 it held $186K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch OTLC in 60 seconds

Price

$0.02

-4.74% on the day · September 28, 2026

52-week range $0.02 to $0.11

Market cap

$11M

P/E

0.0

on FY2025 diluted EPS

What Oncotelic Therapeutics, Inc. does

Oncotelic Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker OTLC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$3.2M	$249.3M	$0.59	n/a
2024	n/a	-$3.6M	-$4.5M	-$0.01	n/a
2023	$70K	-$6.6M	-$7.9M	-$0.02	n/a
2022	n/a	-$9.7M	$5.1M	$0.01	n/a
2021	n/a	-$9.1M	-$9.4M	-$0.03	n/a
2020	$1.7M	-$7.6M	-$9.5M	-$0.11	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 16, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 17, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Oncotelic Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue was $250K; diluted EPS $0.00 versus $0.00.
August 4, 2026
Material agreement 8-K
July 14, 2026
Other event 8-K
July 14, 2026
Executive or director change 8-K
June 29, 2026
Material agreement 8-K
May 14, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
May 5, 2026
Acquisition or sale completed 8-K
April 16, 2026
Other event 8-K
April 15, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS $0.59 versus -$0.01.
April 2, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 23, 2026. Insider transactions on SEC

Insider trades

What the people running Oncotelic Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $10.3K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$10.3K

last 90 days

Sold

last 90 days

Net bought

240,000

$10.3K

Date	Insider	What	Shares	Price	Value	Filing
July 1, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	240,000	$0.04	$10.3K	Form 4
June 24, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	115,000	$0.05	$5.2K	Form 4
June 23, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	75,000	$0.05	$3.4K	Form 4
June 22, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	65,000	$0.05	$2.9K	Form 4
June 22, 2026	Shah Amit B.CFO	Bought	20,000	$0.05	$1K	Form 4
June 17, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	239,759	$0.04	$10.7K	Form 4
June 15, 2026	Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	Bought	96,000	$0.05	$4.3K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns OTLC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 94,503,156 shares in total, about $2.3M at the last price.

Holder	Shares	As of
Trieu VuongCHAIRMAN AND CEO, Director, 10% owner	94,124,319	July 1, 2026
Shah Amit B.CFO	378,837	June 22, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about OTLC

What does Oncotelic Therapeutics, Inc. do?

Oncotelic Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker OTLC.

Is Oncotelic Therapeutics, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $247.5M.

When did Oncotelic Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare OTLC with

Compare OTLC with any company

Follow OTLC

Get an email when Oncotelic Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow OTLC: get an email when it files

Where the numbers come from

Financial figures are the values Oncotelic Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.